NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1320.90 30.30 (2.35%)

29.50% Gain from 52W Low

2.2M NSE+BSE Volume

NSE 06 Jun, 2025 3:31 PM (IST)

110,230.8

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Partnership

Dr. Reddy's Lab and Alvotech to co-develop Keytruda biosimilar drug, with sales of $29.5 bn in 2024 See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

13 May 2025

1320.90

2.35%

Momentum in revenue growth to continue with new launches

Accumulate: Dr. Reddy's Laboratories Ltd.

Target

KRChoksey

During Q4FY25, Dr. Reddy’s revenue stood at INR 85,284 Mn, up 19.9% YoY (+1.8% QoQ), above our estimates by 3.6%, driven by growth across key markets.
EBITDA stood at INR 20,747 Mn, up by 14.4% YoY (-8.7% QoQ), below our estimates by 7.0%, led by contraction in gross margins.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

12 May 2025

1320.90

2.35%

Dr. Reddy's Laboratories (DRRD IN) Q4FY25 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q4FY25 EBITDA was below our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from current level of 16% to +20% in FY27E. Our FY27E EPS stands cut by 4-5%. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and...

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

27 Jan 2025

1320.90

2.35%

Pricing pressure weighs on profitability

Hold: Dr. Reddy's Laboratories Ltd.

Target

KRChoksey

• DRRD revenue, EBITDA, and PAT were largely in-line with our estimates.
• We expect the revenue to grow at 10.3% CAGR and PAT to grow at 5.2% CAGR over FY24-FY27E showing our confidence that the company is getting advanced in the biosimilars pipeline, key launches for cancer therapy and chronic constipation in India and launch of abatacept to gain market share.

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1320.90

2.35%

Soft g-Revlimid sales, high expenses dent earnings

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

DRRD delivered in-line sales (adj. for NRT acquisition and milestone income) and marginally better operational performance in 3QFy25. Revenue/EBITDA YoY growth was moderate due to lower off-take of g-Revlimid and PSAI business, which was offset to some extent by healthy performance in the Russia market

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1320.90

2.35%

Dr Reddys Labs (HOLD): NRT business to require huge marketing spend

Hold: Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

North America sales missed our estimates and reported US$ 395mn in 3QFY25 vs US$ 445mn in 2QFY25 impacted by gRevlimid

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1320.90

2.35%

Core US business weakness coming to the fore

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1320.90

2.35%

Result Update:Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

06 Nov 2024

1320.90

2.35%

Decent print; work on growth levers underway

Hold: Dr. Reddy's Laboratories Ltd.

ICICI Securities Limited

Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment charge of gNuvaring (INR 924mn), was ahead of our expectations

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

06 Nov 2024

1320.90

2.35%

Dr Reddy's Labs (HOLD): Healthy Q2; margins post gRevlimid LOE to remain wary

Hold: Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

Revenue/EBITDA earnings above our and street estimates. APAT ~46% above estimates. Estimates adjusted for JV and impairment cost

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

06 Nov 2024

1320.90

2.35%

Operationally in line; gross margin weakness a clear negative

Sell: Dr. Reddy's Laboratories Ltd.

Emkay

Adjusted for multiple one-offs, Dr Reddy’s’ 2QFY25 PAT was in line with our and street estimates. EBITDA was marginally ahead, aided by a sales beat in Russia and other emerging markets, and lower SG&A.

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Is Dr. Reddy's Laboratories Ltd. worth buying?

509 Votes:

Buy 78.19%

Sell 12.18%

Hold 9.63%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf